Publications by authors named "Cinzia di Giuli"
Background: Management of immunocompromised COVID-19 patients is the object of current debate. Accumulating evidence suggest that treatment with high-titer COVID-19 convalescent plasma (CCP) may be effective in this characteristic clinical scenario.
Case Report: A 52-years old immunocompromised female patient, previously treated with rituximab for low grade B-cell lymphoma, showed prolonged SARS-CoV-2 shedding and a long-term course of signs of severe COVID-19.
Article Synopsis
- SARS-CoV-2 is the virus causing COVID-19, and it can lead to a dangerous inflammatory response known as a "cytokine storm" (CS), which significantly worsens patient outcomes.
- A new "Cytokine Storm Score" (CSs) has been proposed to identify COVID-19 patients at risk of severe hyperinflammation, enabling timely treatment to improve survival rates.
- Research conducted at St. Maria Hospital analyzed patients with confirmed SARS-CoV-2 infections to validate the CSs, aiming to promptly manage cases to prevent severe complications, such as intubation.
Myocarditis is an inflammatory disease of the myocardium. Viruses, such as enterovirus, adenovirus, parvovirus B19, HHV6 or cytomegalovirus (CMV) and autoimmune diseases are recognized causes of myocarditis. We describe the clinical case of a young Indian woman with SLE and a concomitant acute CMV related myocarditis with favourable outcome after ganciclovir therapy.
View Article and Find Full Text PDFBackground/aims: In 2002, the first reported outbreak of hepatitis A virus (HAV) infection involving mostly intravenous drug users (IDU) occurred in Italy. We attempted a thorough evaluation of the outbreak, including epidemiological, clinical and virological analyses.
Methods: We conducted an epidemiological investigation, including a case-control study, to identify the source and the modes of HAV transmission.